Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib or Cediranib/Olaparib vs Platinum-Based Chemotherapy in Recurrent Ovarian Cancer
NCT02446600Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2016
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of olaparib and cediranib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Progression Free Survival. Started Mar 2016; status: active, not recruiting.
02
Drugs
olaparibcediranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02446600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02446600.